Literature DB >> 20210721

Cardiovascular drugs inducing QT prolongation: facts and evidence.

Carlos A Taira1, Javier A W Opezzo, Marcos A Mayer, Christian Höcht.   

Abstract

Acquired QT syndrome is mainly caused by the administration of drugs that prolong ventricular repolarization. On the other hand, the risk of drug-induced torsades de pointes is increased by numerous predisposing factors, such as genetic predisposition, female sex, hypokalemia and cardiac dysfunction. This adverse reaction is induced by different chemical compounds used for the treatment of a variety of pathologies, including arrhythmias. As it is known, antiarrhythmic agents and other cardiovascular drugs can prolong the QT interval, causing this adverse reaction. Of the 20 most commonly reported drugs, 10 were cardiovascular agents and these appeared in 348 of the reports (46%). Class Ia antiarrhythmic agents have frequently been linked to inducing arrhythmia, including torsades de pointes. Sotalol and amiodarone, class III antiarrhythmics, are known to prolong the QT interval by blocking I(Kr). Due to the severity of events caused by the therapeutic use of these drugs, in this work of revision the cardiovascular drugs that present this property and the factors and evidence will be mentioned.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20210721     DOI: 10.2174/157488610789869229

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  7 in total

1.  Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.

Authors:  Jeffrey K Aronson
Journal:  Drug Saf       Date:  2013-03       Impact factor: 5.606

Review 2.  Loperamide cardiotoxicity: "A Brief Review".

Authors:  Tamer Akel; Soad Bekheit
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-11-10       Impact factor: 1.468

3.  Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo.

Authors:  Jürgen Biermann; Kezhong Wu; Katja E Odening; Stefan Asbach; Gideon Koren; Xuwen Peng; Manfred Zehender; Christoph Bode; Michael Brunner
Journal:  Eur J Pharmacol       Date:  2010-10-17       Impact factor: 4.432

4.  Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.

Authors:  Istvan Baczko; David Liknes; Wei Yang; Kevin C Hamming; Gavin Searle; Kristian Jaeger; Zoltan Husti; Viktor Juhasz; Gergely Klausz; Robert Pap; Laszlo Saghy; Andras Varro; Vernon Dolinsky; Shaohua Wang; Vivek Rauniyar; Dennis Hall; Jason Rb Dyck; Peter E Light
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

5.  Life-threatening cardiac arrhythmias due to drug-induced QT prolongation : A retrospective study over 6 years from a medical intensive care unit.

Authors:  G Michels; M Kochanek; R Pfister
Journal:  Med Klin Intensivmed Notfmed       Date:  2015-09-04       Impact factor: 0.840

6.  Use of antiarrhythmic drugs in elderly patients.

Authors:  Hon-Chi Lee; Kristin Tl Huang; Win-Kuang Shen
Journal:  J Geriatr Cardiol       Date:  2011-09       Impact factor: 3.327

Review 7.  Combining wet and dry research: experience with model development for cardiac mechano-electric structure-function studies.

Authors:  T Alexander Quinn; Peter Kohl
Journal:  Cardiovasc Res       Date:  2013-01-17       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.